华仁药业
(300110)
| 流通市值：43.68亿 | | | 总市值：43.74亿 |
| 流通股本：11.80亿 | | | 总股本：11.82亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 406,703,155.73 | 1,636,256,356.79 | 1,215,927,751.99 | 829,046,309.5 |
| 营业收入 | 406,703,155.73 | 1,636,256,356.79 | 1,215,927,751.99 | 829,046,309.5 |
| 二、营业总成本 | 340,912,234.64 | 1,404,815,482.92 | 1,032,296,689.68 | 720,954,485.3 |
| 营业成本 | 235,725,086.42 | 937,201,978.55 | 682,901,948.96 | 479,424,945.73 |
| 税金及附加 | 6,240,526.91 | 24,561,091.66 | 18,136,148.5 | 12,571,875.5 |
| 销售费用 | 42,875,979.11 | 213,989,966.04 | 163,089,193.12 | 116,290,006.12 |
| 管理费用 | 21,898,219.86 | 97,040,349.35 | 73,912,589.73 | 49,861,726.28 |
| 研发费用 | 18,160,646.77 | 68,681,402.99 | 43,426,283.82 | 28,557,990.51 |
| 财务费用 | 16,011,775.57 | 63,340,694.33 | 50,830,525.55 | 34,247,941.16 |
| 其中:利息费用 | 15,255,129.83 | 61,514,816.75 | 47,388,034.96 | 32,220,353.16 |
| 其中:利息收入 | -249,437.5 | 2,158,302.79 | 745,028.79 | 562,950.93 |
| 加:投资收益 | - | 843,779.33 | 301,571.34 | 301,571.34 |
| 资产处置收益 | - | 4,352,591.47 | 4,592,138.36 | 4,599,916.21 |
| 资产减值损失(新) | -1,451,480.86 | -9,468,366.55 | 365,655.33 | -535,924.07 |
| 信用减值损失(新) | -8,842,393.38 | -12,425,192.79 | -37,610,185.56 | -25,090,321.37 |
| 其他收益 | 3,183,239.65 | 11,200,637.97 | 3,468,830.26 | 1,068,552.37 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 58,680,286.5 | 225,944,323.3 | 154,749,072.04 | 88,435,618.68 |
| 加:营业外收入 | 17,202.92 | 6,894,694.44 | 3,165,356 | 2,782,963.81 |
| 减:营业外支出 | 998,477.74 | 2,324,347.7 | 700,338.97 | 500,829.83 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 57,699,011.68 | 230,514,670.04 | 157,214,089.07 | 90,717,752.66 |
| 减:所得税费用 | 5,320,827.34 | 37,089,934.89 | 16,563,098.56 | 6,279,569.67 |
| 六、净利润 | 52,378,184.34 | 193,424,735.15 | 140,650,990.51 | 84,438,182.99 |
| 持续经营净利润 | 52,378,184.34 | 193,424,735.15 | 140,650,990.51 | 84,438,182.99 |
| 归属于母公司股东的净利润 | 50,822,916.88 | 188,063,014.38 | 137,083,571.59 | 82,281,868.89 |
| 少数股东损益 | 1,555,267.46 | 5,361,720.77 | 3,567,418.92 | 2,156,314.1 |
| (一)基本每股收益 | 0.04 | 0.16 | 0.12 | 0.07 |
| (二)稀释每股收益 | 0.04 | 0.16 | 0.12 | 0.07 |
| 九、综合收益总额 | 52,378,184.34 | 193,424,735.15 | 140,650,990.51 | 84,438,182.99 |
| 归属于母公司股东的综合收益总额 | 50,822,916.88 | 188,063,014.38 | 137,083,571.59 | 82,281,868.89 |
| 归属于少数股东的综合收益总额 | 1,555,267.46 | 5,361,720.77 | 3,567,418.92 | 2,156,314.1 |
| 公告日期 | 2024-04-25 | 2024-04-25 | 2023-10-25 | 2023-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |